查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601256

罕见疾病基因检测市场：按疾病类型、技术、专业和最终用户划分 - 全球预测 2025-2030

Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年罕见疾病基因检测市场规模为13.3亿美元，预计2024年将达15.4亿美元，复合年增长率为16.15%，预计到2030年将达38亿美元。

罕见疾病基因检测是一种诊断测试，可识别导致罕见疾病的基因突变，这些疾病通常影响分布在世界各地的小部分患者群体。该领域的需求源于其在提供早期诊断、个人化医疗和针对性治疗选择方面的重要作用，特别是当传统治疗失败时。基因检测主要应用于临床和研究环境，以支持知情的临床决策、病患咨询和药物开发，最终用途扩展到医院、诊断中心和研究机构。基因检测的成长是由基因序列测定技术的进步、意识的提高以及政府对罕见疾病研究的支持政策所推动的。此外，增加对製药公司的投资以及与诊断公司的合作也提供了巨大的成长机会。对伴同性诊断和精准医疗的需求不断增长增加了市场潜力，而 IT 支援的远端医疗解决方案则促进了测试的进行。

主要市场统计
基准年[2023] 13.3亿美元
预测年份 [2024] 15.4亿美元
预测年份 [2030] 38亿美元
复合年增长率（%） 16.15%

然而，该市场面临高成本、监管挑战、基因资料隐私的伦理问题以及新兴地区知名度低等限制。解决这些挑战需要策略定价、监管清晰度和更强有力的隐私保护。创新热点包括开发负担得起的测序技术、用于预测分析的人工智慧整合、用于资料解释的先进生物资讯学工具以及个人化数位健康平台。利用市场机会的关键建议包括促进与分子诊断公司的合作、利用巨量资料分析以及建立以患者为中心的解决方案以增强遗传咨询师与患者的互动。这个市场是研究集中且高度专业的，需要对基因组学和监管环境有深入的了解。生物技术、资料分析和医疗保健的融合有望形成一个生态系统，该生态系统将产生新的治疗途径和创新的护理途径，为罕见疾病管理的突破和可能扰乱市场条件铺平道路。透过克服监管和成本挑战，公司可以将自己定位为这个不断发展的领域的领导者。

市场动态：快速发展的罕见疾病基因检测市场的关键市场洞察

供需的动态交互作用正在改变罕见疾病基因检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 罕见遗传疾病的流行以及早期快速诊断的必要性
    • 越来越多地使用翻译和基因组研究来识别新突变
    • 政府在罕见疾病诊断和治疗方面的倡议
  • 市场限制因素
    • 道德问题和罕见疾病资讯的获取有限
  • 市场机会
    • 基因技术的进步识别新的罕见疾病基因
    • 罕见遗传疾病诊断的获利投资
  • 市场挑战
    • 与新的罕见疾病基因检测核准程序相关的严格规定

波特五力：驾驭罕见疾病基因检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解罕见疾病基因检测市场的外部影响

外部宏观环境因素对罕见疾病基因检测市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解罕见疾病基因检测市场竞争状况

罕见疾病基因检测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 罕见疾病基因检测市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估罕见疾病基因检测市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 罕见遗传疾病的流行以及早期快速诊断的必要性
      • 越来越多地使用转化研究和基因组监测来识别新变异
      • 政府关于罕见疾病诊断和治疗的倡议
    • 抑制因素
      • 伦理问题和罕见疾病资讯的获取有限
    • 机会
      • 基因技术的进步识别新的罕见疾病基因
      • 罕见遗传疾病诊断的获利投资
    • 任务
      • 新罕见疾病基因检测核准流程的严格规定
  • 市场区隔分析
    • 疾病类型：开发先进检测方法，满足罕见遗传疾病筛检需求
    • 最终用户：学术研究实验室稀有基因测试的新研究
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章 罕见疾病基因检测市场：依疾病类型

  • 癌症
  • 心血管疾病
  • 皮肤科疾病
  • 内分泌/代谢疾病
  • 血液疾病
  • 免疫疾病
  • 肌肉骨骼疾病
  • 神经系统疾病

第七章 罕见疾病基因检测市场：依技术分类

  • 阵列技术
  • 鱼
  • 核型分析
  • 次世代定序
    • 全EXOME定序
    • 全基因组序列分析
  • 基于PCR的测试
  • 桑格序列

第八章 罕见疾病基因检测市场：依专业划分

  • 生化基因检测
  • 染色体基因检测
  • 分子遗传学检测

第九章 罕见疾病基因检测市场：依最终用户分类

  • 诊断实验室
  • 医院/诊所
  • 研究机构和 CRO

第十章 美洲罕见疾病基因检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太罕见疾病基因检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东、非洲罕见疾病基因检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Burjeel Holdings与美国Bridgebio Pharma合作启动罕见疾病研发计划“Nader”
    • 美国国立卫生研究院 (NIH) 投入 1.4 亿美元研究正常人体细胞和组织的遗传变异
    • CENTOGENE 宣布推出新的 CentoGenome 全基因组定序解决方案，用于诊断罕见和神经退化性疾病

公司名单

  • Laboratory Corporation Of America Holdings
  • Biora Therapeutics, Inc.
  • 3billion, Inc.
  • Caris Life Sciences
  • Ambry Genetics Corporation
  • OPKO Health, Inc.
  • Color Health, Inc.
  • Quest Diagnostics Incorporated
  • Nonacus Limited
  • Integrated DNA Technologies, Inc. by Danaher Corporation
  • Myriad Genetics, Inc.
  • Blueprint Genetics Oy
  • PerkinElmer Inc.
  • Macrogen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Variantyx, Inc.
  • Centogene NV
  • Fulgent Genetics, Inc.
  • Genomelink, Inc.
  • Illumina, Inc.
  • GeneDx, LLC
  • Invitae Corporation
  • Sanofi SA
  • Helix OpCo, LLC
  • Arup Laboratories
  • The Cooper Companies, Inc.
  • QIAGEN NV
  • Realm IDX, Inc.
  • Baylor Genetics
  • Thermo Fisher Scientific Inc.
Product Code: MRR-B9334AD6C623

The Rare Disease Genetic Testing Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 16.15%, to USD 3.80 billion by 2030.

Rare disease genetic testing involves diagnostic tests to identify gene mutations causing rare disorders, often affecting small patient populations scattered globally. This field's necessity stems from the critical role it plays in early diagnosis, personalized medicine, and providing targeted treatment options, especially when traditional therapies fail. Primarily applied in clinical and research settings, genetic testing supports informed clinical decisions, patient counseling, and drug development, with end-use scope spanning hospitals, diagnostic centers, and research institutes. The growth of genetic testing is driven by advances in genome sequencing technologies, increased awareness, and supportive government policies for rare disease research. Additionally, the increase in pharmaceutical investments and collaborations with diagnostic companies represents significant growth opportunities. A rise in demand for companion diagnostics and precision medicine amplifies market potential, while IT-enabled telehealth solutions ease testing accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 1.33 billion
Estimated Year [2024] USD 1.54 billion
Forecast Year [2030] USD 3.80 billion
CAGR (%) 16.15%

However, the market faces limitations like high costs, regulatory challenges, ethical concerns around genetic data privacy, and limited awareness in developing regions. These challenges necessitate strategic pricing, clearer regulatory frameworks, and privacy protection advancements to foster market expansion. Innovation hotspots include the development of affordable sequencing technologies, integration of AI for predictive analytics, advanced bioinformatics tools for data interpretation, and personalized digital health platforms. Key recommendations to capitalize on market opportunities include fostering collaborations with molecular diagnostic firms, leveraging big data analytics, and establishing patient-centric solutions that enhance interaction between genetic counselors and patients. The nature of this market is research-intensive and highly specialized, requiring a keen understanding of genomic science and regulatory landscapes. The convergence of biotechnology, data analytics, and healthcare promises a generative ecosystem for novel therapeutic avenues and innovative care pathways, paving the way for breakthroughs in rare disease management and potentially disrupting the market landscape. By navigating regulatory and cost challenges, businesses can position themselves as leaders in this evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
    • Rising Use in Translational & Genomic Research for Identification of Novel Mutations
    • Government Initiatives for Diagnosis and Treatment of Rare Diseases
  • Market Restraints
    • Ethical Concerns and Access to Limited Information on Rare Disease
  • Market Opportunities
    • Advancements in Genetic Technology to Identify New Rare Disease Genes
    • Favorable Investments for Diagnosis of Rare Genetic Diseases
  • Market Challenges
    • Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test

Porter's Five Forces: A Strategic Tool for Navigating the Rare Disease Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Disease Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Disease Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Disease Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Disease Genetic Testing Market

A detailed market share analysis in the Rare Disease Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Disease Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Disease Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Laboratory Corporation Of America Holdings, Biora Therapeutics, Inc., 3billion, Inc., Caris Life Sciences, Ambry Genetics Corporation, OPKO Health, Inc., Color Health, Inc., Quest Diagnostics Incorporated, Nonacus Limited, Integrated DNA Technologies, Inc. by Danaher Corporation, Myriad Genetics, Inc., Blueprint Genetics Oy, PerkinElmer Inc., Macrogen, Inc., F. Hoffmann-La Roche Ltd., Variantyx, Inc., Centogene N.V., Fulgent Genetics, Inc., Genomelink, Inc., Illumina, Inc., GeneDx, LLC, Invitae Corporation, Sanofi S.A., Helix OpCo, LLC, Arup Laboratories, The Cooper Companies, Inc., QIAGEN N.V., Realm IDX, Inc., Baylor Genetics, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Cancer, Cardiovascular Disorders, Dermatology Diseases, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
  • Based on Technology, market is studied across Array Technology, FISH, Karyotyping, Next Generation Sequencing, PCR - Based Testing, and Sanger Sequencing. The Next Generation Sequencing is further studied across Whole Exome Sequencing and Whole Genome Sequencing.
  • Based on Specialty, market is studied across Biochemical Genetic Tests, Chromosomal Genetic Tests, and Molecular Genetic Tests.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
      • 5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
      • 5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
      • 5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
    • 5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Rare Disease Genetic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Cancer
  • 6.3. Cardiovascular Disorders
  • 6.4. Dermatology Diseases
  • 6.5. Endocrine & Metabolism Diseases
  • 6.6. Hematology Diseases
  • 6.7. Immunological Disorders
  • 6.8. Musculoskeletal Disorders
  • 6.9. Neurological Disorders

7. Rare Disease Genetic Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Array Technology
  • 7.3. FISH
  • 7.4. Karyotyping
  • 7.5. Next Generation Sequencing
    • 7.5.1. Whole Exome Sequencing
    • 7.5.2. Whole Genome Sequencing
  • 7.6. PCR - Based Testing
  • 7.7. Sanger Sequencing

8. Rare Disease Genetic Testing Market, by Specialty

  • 8.1. Introduction
  • 8.2. Biochemical Genetic Tests
  • 8.3. Chromosomal Genetic Tests
  • 8.4. Molecular Genetic Tests

9. Rare Disease Genetic Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Laboratories & CROs

10. Americas Rare Disease Genetic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Rare Disease Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project 'Nader' In Partnership With US-Based Bridgebio Pharma
    • 13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
    • 13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

Companies Mentioned

  • 1. Laboratory Corporation Of America Holdings
  • 2. Biora Therapeutics, Inc.
  • 3. 3billion, Inc.
  • 4. Caris Life Sciences
  • 5. Ambry Genetics Corporation
  • 6. OPKO Health, Inc.
  • 7. Color Health, Inc.
  • 8. Quest Diagnostics Incorporated
  • 9. Nonacus Limited
  • 10. Integrated DNA Technologies, Inc. by Danaher Corporation
  • 11. Myriad Genetics, Inc.
  • 12. Blueprint Genetics Oy
  • 13. PerkinElmer Inc.
  • 14. Macrogen, Inc.
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Variantyx, Inc.
  • 17. Centogene N.V.
  • 18. Fulgent Genetics, Inc.
  • 19. Genomelink, Inc.
  • 20. Illumina, Inc.
  • 21. GeneDx, LLC
  • 22. Invitae Corporation
  • 23. Sanofi S.A.
  • 24. Helix OpCo, LLC
  • 25. Arup Laboratories
  • 26. The Cooper Companies, Inc.
  • 27. QIAGEN N.V.
  • 28. Realm IDX, Inc.
  • 29. Baylor Genetics
  • 30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. RARE DISEASE GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RARE DISEASE GENETIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 244. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023